Table 4.
Dominant SARS-CoV B Cell Epitope Regions
SARS-CoV |
SARS-CoV-2 |
||||
---|---|---|---|---|---|
Sequence | Max RF | Sequence | Proteina | Mapped Start–End | Identity (%) |
DAVDCSQNPLAELKCSVKSFEIDKGIYQTSNF | 0.504 | DAVDCALDPLSETKCTLKSFTVEKGIYQTSN | S | 287–317 | 69 |
VCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVIT | 0.745 | VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVI | S | 524–598 | 80 |
GTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNN | 0.709 | GTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGS | S | 601–640 | 78 |
FSQILPDPLKPTKRSFIED | 0.365 | FSQILPDPSKPSKRSFIE | S | 802–819 | 89 |
FGAGAALQIPFAMQMAYRFNGIG | 0.367 | FGAGAALQIPFAMQMAYRFNGI | S | 888–909 | 100 |
MADNGTITVEELKQLLEQWNLVIG | 0.460 | MADSNGTITVEELKKLLEQWNLVI | M | 1–24 | 92 |
PLMESELVIGAVIIRGHLRMA | 0.457 | PLLESELVIGAVILRGHLRI | M | 132–151 | 90 |
PQGLPNNTASWFTALTQHGKEE | 0.537 | RPQGLPNNTASWFTALTQHGK | N | 42–62 | 95 |
NNAATVLQLPQGTTLPKGFYA | 0.543 | NNNAATVLQLPQGTTLPKGF | N | 153–172 | 95 |
KHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDD | 0.82 | NKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADM | N | 355–401 | 90 |
S, surface glycoprotein; M, membrane protein; N, nucleocapsid phosphoprotein